UNCY Logo.jpg
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
03 sept. 2024 07h03 HE | Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
UNCY Logo.jpg
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 07h10 HE | Unicycive Therapeutics, Inc.
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company”...
UNCY Logo.jpg
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
17 juil. 2024 07h03 HE | Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
UNCY Logo.jpg
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
11 juil. 2024 07h03 HE | Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Image1
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
10 juil. 2024 07h03 HE | Unicycive Therapeutics, Inc.
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE...
UNCY Logo.jpg
Unicycive Therapeutics Joins Russell Microcap® Index
01 juil. 2024 07h03 HE | Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Tolerability
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
25 juin 2024 07h30 HE | Unicycive Therapeutics, Inc.
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS...
Novartis' Fabhalta S
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
13 juin 2024 11h39 HE | Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
purespring logo.png
Purespring Therapeutics presents preclinical data at the 61st ERA Congress
24 mai 2024 10h57 HE | Purespring Therapeutics
Purespring Therapeutics presents preclinical data at the 61st ERA Congress Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to...
UNCY Logo.jpg
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
23 mai 2024 07h03 HE | Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...